Project Title:
Exploiting BH3 Mimetic Drugs to Drive Apoptosis in Prostate Cancer
Project Overview:
BH3 mimetic drugs are a promising new class of treatments that may have efficacy in prostate cancer with the proper therapeutic approaches. Dr. Balk and team will investigate how to use BH3 mimetic drugs as precision medicine treatments in prostate cancer patients, as well as how these treatments can be combined with other agents to have efficacy in broader prostate cancer patient populations.
Principle Investigators:
Institute of Cancer Research
Johann de Bono, MD, PhD
University of Washington
Eva Corey, PhD
University of British Columbia
Yuzhuo Wang, PhD
Additional Investigators:
Harvard: Beth Israel Deaconess Medical Center
Andreas Varkaris, MD, PhD
David Einstein, MD
Institute of Cancer Research
Adam Sharp, MD, PhD